Compare KD & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | LEGN |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 5.9B |
| IPO Year | 2021 | 2020 |
| Metric | KD | LEGN |
|---|---|---|
| Price | $12.35 | $18.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $35.25 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 4.7M | 1.7M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.95 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $15,057,000,000.00 | N/A |
| Revenue This Year | $3.96 | $46.27 |
| Revenue Next Year | $0.41 | $28.77 |
| P/E Ratio | $16.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $16.24 |
| 52 Week High | $43.74 | $45.30 |
| Indicator | KD | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 49.02 |
| Support Level | $11.34 | $17.46 |
| Resistance Level | $13.81 | $23.68 |
| Average True Range (ATR) | 0.51 | 0.81 |
| MACD | 0.45 | 0.16 |
| Stochastic Oscillator | 42.98 | 47.10 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.